Test Price
2,800 AED✅ Home Collection Available
ANKRD26 Gene Thrombocytopenia Type 2 Genetic Test in Dubai
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited next-generation sequencing.
- Premium Logistics: VIP mobile phlebotomy with temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post-test interpretation with a DHA-licensed genetic counsellor.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The ANKRD26 Gene Thrombocytopenia Type 2 Genetic Test detects pathogenic variants in the ANKRD26 gene responsible for inherited thrombocytopenia-2 (THC2), a bleeding disorder characterised by low platelet counts. This DHA-compliant assay delivers definitive molecular confirmation for at-risk families and informs personalised haematological management. Next-generation sequencing (NGS) is employed to provide full gene coverage, identifying point mutations, small insertions and deletions, and copy number changes with high analytical sensitivity.
| Feature | Our Test (NGS Panel) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Next-generation sequencing (NGS) – full gene coverage | Sanger sequencing – limited to known hotspots |
| Analytical Sensitivity | >99.9% | ~95% for targeted regions |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Variant Detection | Point mutations, small indels, copy number changes | Point mutations only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), Consultant Medical Genetics, states: “A confirmed pathogenic variant in ANKRD26 necessitates correlation with the full haematological profile and three-generation pedigree. I recommend that all family members of a proband receive targeted genetic counselling before pursuing cascade screening, and that patients maintain their current medication regimen until formally reviewed by their specialist.”
Medication Advisory
⚠️ Do not stop or modify any anticoagulant, anti-platelet, or prescribed therapy without prior discussion with your treating physician. Sudden changes may elevate bleeding risk.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Individuals unable to provide informed consent, those experiencing active severe haemorrhage requiring urgent intervention, or patients who cannot safely undergo phlebotomy.
- ER Red Flags: Sudden onset of extensive bruising, petechiae (pinpoint red spots), mucosal bleeding (nose, gums), blood in urine or stool, or any indication of intracranial bleeding – seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. What is the ANKRD26 gene test and why is it performed?
This advanced genetic test identifies mutations in the ANKRD26 gene that cause thrombocytopenia type 2, a hereditary bleeding disorder characterised by persistently low platelet counts. It confirms the diagnosis in symptomatic individuals, enables predictive testing for at-risk family members, and helps haematologists tailor long-term surveillance and treatment strategies.
2. How is the sample collected and what preparation is required?
A simple blood sample is collected from a vein in your arm. No fasting is necessary, but pre-test genetic counselling is mandatory. Our certified phlebotomist visits your preferred location daily from 8 AM to 11 PM, collects a small volume of whole blood, and transports it under strict cold-chain conditions to our ISO-accredited laboratory.
3. How long do results take and how are they interpreted?
Results are delivered within 3–4 weeks and are interpreted by a DHA-licensed consultant medical geneticist. A report identifying a pathogenic variant confirms the diagnosis of thrombocytopenia type 2. A negative result reduces the likelihood of ANKRD26-related thrombocytopenia but does not eliminate all hereditary causes; your genetic counsellor will explain the implications and recommend next steps.
UAE Regulatory & Data Privacy Adherence
This service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical genetic testing and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our facility holds ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139) and operates under DHA and MOHAP standard nomenclature.
Clinical & Logistical Metadata
| Test Name | ANKRD26 Gene Thrombocytopenia Type 2 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood |
| Methodology Used | Next-generation sequencing (NGS) – full gene coverage |
| ICD-10-CM Code | D69.4 |
| LOINC Code | 21673-3 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians